A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

Jonathan W. Riess, Karen Kelly, Paul Wheatley‐Price et al.|Journal of Clinical Oncology|2021

Cited by 10